Barani Kumar Rajendran

Barani Kumar Rajendran serves as an Associate Research Scientist in the Department of Pathology at Yale School of Medicine. He is a key member of the Schalper Lab, which focuses on understanding the immunobiology of human solid tumors and developing molecular biomarkers for predicting therapy responses. His work is situated within Yale's robust cancer research ecosystem, collaborating with multiple departments including Medical Oncology and Hematology.

• Yale School of Medicine, Department of Pathology
• Member of Schalper Lab (Translational Immuno-oncology Laboratory)
• Collaborations across Yale Cancer Center and Yale Center for Immuno-Oncology

Dr. Rajendran's research spans multiple cutting-edge domains at the intersection of computational biology and cancer immunology. His work integrates bioinformatics, next-generation sequencing, and single-cell research to advance precision medicine approaches. He specializes in analyzing tumor microenvironments, particularly focusing on immune evasion mechanisms in lung cancer and biomarker development for immunotherapy response prediction. His expertise in computational structural biology and spatial transcriptomics enables novel approaches to understanding cancer biology at the molecular level.

His recent publications reveal a strong focus on immune evasion mechanisms in lung cancer, particularly examining how tumor cells avoid immune detection through pathways like TAP2 downregulation. His work also extends to diabetic complications research, cancer diagnostics through biomarker development, and nanotechnology applications in oncology. The interdisciplinary nature of his research bridges computational biology with clinical applications, aiming to translate molecular insights into improved cancer diagnostics and treatment strategies.

Dr. Rajendran actively contributes to the scientific community through editorial roles, serving as a Guest Editor for Frontiers in Medicine and Frontiers in Bioinformatics, and as an Editorial Board Member for Pharmacognosy Magazine. He also regularly reviews manuscripts for Scientific Reports and Frontiers in Oncology, demonstrating his standing within the research community.

As a member of the Schalper Lab, Dr. Rajendran collaborates with principal investigator Kurt Schalper, MD, PhD, and works alongside other researchers including Dianqing (Dan) Wu, Hongyue Zhou, Julie Goodwin, Kishu Ranjan, and Wenwen Tang. His computational expertise complements the lab's mission to develop objective, quantitative measures of immunotherapy-related biomarkers in immune cells and cancer tissues, contributing significantly to Yale's translational cancer research efforts.